Genelux
GNLXGenelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogen …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Genelux
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/25/2026 | Sell | Smalling, Ralph | Head of Regulatory | $2.5 | $602 |
| 3/24/2026 | Sell | Zindrick, Thomas | President and CEO | $2.4 | $8,668 |
| 3/24/2026 | Sell | Yu, Yong | SVP, Clinical Development | $2.4 | $2,193 |
| 3/24/2026 | Sell | Cappello, Joseph | Chief Technical Officer | $2.4 | $2,193 |
| 3/24/2026 | Sell | Smalling, Ralph | Head of Regulatory | $2.4 | $835 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)